Boston Scientific (BSX) Rises Higher Than Market: Key Facts
How to find the "alpha" market in U.S. stocks next year? Goldman Sachs provides an investment guide.
Zhihui Finance has learned that Goldman Sachs analysts said in a report that over the next six months, the materials, Software, and services industries in the USA are most likely to outperform the Large Cap. Goldman Sachs strategist David Kostin stated in a report on December 20 that they introduced a model for USA Stocks to select industries expected to exceed the benchmark Index by 5 percentage points or more, "to identify 'high conviction' views with significant Alpha potential." He noted, "Our model incorporates macro, fundamental, and valuation data as independent variables. We run probability models separately for each Industry, only including
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Vivani Medical (VANI) and Merit Medical Systems (MMSI)
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $100
Truist Financial Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $110
Boston Scientific Updates Instructions for Cryoablation Balloons After Reports Of Severe Injuries
J.P. Morgan's Top Healthcare Stocks for 2025
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
Here's Why Boston Scientific (NYSE:BSX) Has Caught The Eye Of Investors
Boston Scientific Hits 4-week Low
RBC Capital Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $105
Boston Sci Issues Safety Recall for POLARx Cryoablation Catheters
Express News | Boston Scientific Shares Extend Losses, Last Down 1.7% at $88.90
Express News | FDA: There Have Been Seven Reported Injuries & Four Reports of Death Related to Boston Scientific's Polarx Cryoablation Balloon Catheters
Express News | FDA: Boston Scientific Updates Use Instructions for Polarx & Polarx Fit Cryoablation Balloon Catheters Over Many Reports of Atrio-Esophageal Fistula
Least Shorted S&P 500 Stocks in November
Truist Financial Maintains Boston Scientific(BSX.US) With Buy Rating, Announces Target Price $110
Pain Management Devices Global Analysis Report 2024-2034 Featuring Abbott Laboratories, Boston Scientific, Medtronic, Nevro, Baxter, OMRON, Stryker, Teleflex, ICU Medical, AtriCure, and Zynex
Boston Scientific (BSX) Stock Moves -0.03%: What You Should Know